Rubella Vaccine Market size is forecast to reach 4.3 billion by 2025, growing at a CAGR of 6.07 during the forecast period 2020-2025. Rubella is a contagious infection which is caused by the transmission of airborne droplets of infected people through coughing or sneezing. Increase in the incidence of rubella infection and increase in the infection which results in congenital defects known as congenital rubella syndrome are the major factors driving the growth of the market is set to further enhance the overall market demand of rubella vaccine during the forecast period 2020-2025.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=502008
Report Price: $ 4500 (Single User License)
End User- Segment Analysis
Rubella is a severe and infectious disease triggered by a virus. Pediatric vaccines are given in two doses. First at the age of 15 months and second is before the age of six. Pediatric vaccines are more effective than adult vaccines. Adult vaccine is only single dose vaccine. Both vaccines contain small amounts of neomycin and gelatin. They are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Pediatric Vaccines is forecast to be the fastest growing with a CAGR of 7.15% during the forecast period 2020-2025. This is owing to the growing initiatives for immunization against diseases.
Application – Segment Analysis
Hospital Pharmacies dominates the rubella vaccine market owing to growing industrialization which is leading to propel the airborne diseases globally and the symptoms related to airborne diseases include fever, cough, redness in the eyes and running nose coupled with rashes in the body. Increase in the success rate of vaccination schemes depends on government initiatives of each country. Rubella vaccine is also used in drug stores and retail pharmacies. Hospital pharmacies is set to be the fastest growing segment of the rubella vaccine market during the forecast period 2020-2025.
Geography – Segment Analysis
North America dominates the rubella vaccine market with a share of more than 37.1%, followed by Europe owing to the high awareness about the disease and vaccination ,Increasing government immunization programs and manufactures supports to provide cost-effective vaccines is driving the growth of the rubella vaccine market in the forecast period 2020-2025.
However, Europe is estimated to grow at a highest CAGR during the forecast period 2020-2025 owing to the increasing government vaccination programs and growing investments in vaccination. Increasing healthcare expenditure, government initiatives, increasing per capita income and the expansion of vaccination programs by the government to increase prevention from infectious disease is boosting the growth of the rubella vaccine market in Europe region
Talk to one of our sales representative about the full report by providing your details in the link below:
Drivers – Rubella Vaccine Market
Increase in government focus on rubella vaccination is increasing the demand of the rubella vaccine market owing to the rising government and non-government funding for rubella vaccine development and the high prevalence of diseases. Increasing investment by companies, increasing global vaccination coverage and growing immunization programs is estimated to propel the growth of rubella vaccines market. Rubella can cause serious birth deficiencies in developing baby if a woman is infected when she is pregnant. The best method to protect against rubella and measles is measles-rubella (MR) vaccines which give long-term immunity and for this various government and organizations are conducting preventive programs.
Increase in the infection which results in congenital defects is increasing the demand of the rubella vaccine market owing to the increasing number of incidences and prevalence of the disease. The virus replicates in the respiratory tract and is transmitted to others via respiratory secretions through aerosolized droplets in closed areas and appearance of symptoms is 10-12 days after the infection which is usually fever. Rubella vaccine should not be given to the individuals who are on immunosuppressants as the virus can replicate and cause infections. There is no cure for congenital rubella syndrome, and it is important to prevent it and for the prevention of congenital defects MMR (measles, mumps, rubella) vaccine is given at least 28 days beforehand.
Challenges – Rubella Vaccine Market
Some of the factors that impede the growth of the rubella vaccine market are reactions related to vaccinations and insufficient yield with high selectivity of human diploid cell while constructing rubella vaccines.
Rubella Vaccine Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Rubella Vaccine Market. In 2019, Rubella Vaccine Market share is consolidated by the top ten players present in the market. Rubella Vaccine top 10 companies are Merck & Co. Inc., GlaxoSmithKline Plc, Sanofi Aventis, Pfizer Inc., Blerna Biotech, Serum Institute of India, Astellas Pharma Inc., CSL Limited and Chiron Corporation, among others.
Meningococcal Conjugate Vaccine Market
Pneumococcal Polysaccharide Vaccine Market
IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to firstname.lastname@example.org to discuss more about our consulting services.